Format

Send to

Choose Destination
Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18.

Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Author information

1
Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43–45, 8200 Aarhus C., Denmark. dc@dce.au.dk

Abstract

Adjuvant tamoxifen therapy of breast cancer patients with estrogen receptor-positive tumors reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized by several polymorphic enzymes, including cytochrome P450 2D6 (CYP2D6), to more active metabolites. We have reviewed the clinical pharmacology of tamoxifen and evaluated the evidence from clinical epidemiology studies regarding the association between CYP2D6 inhibition and tamoxifen effectiveness. We conclude that the impact of CYP2D6 inhibition on tamoxifen effectiveness is likely to be null or small, at least in the populations studied so far. Understanding the effect of variations in tamoxifen metabolism on breast cancer outcomes, if any, will likely require a broader perspective, including examination of the complete metabolic pathway and subgroups of patients with other markers of potentially poor tamoxifen response.

KEYWORDS:

breast cancer; breast cancer recurrence; cytochrome P450 2D6; selective serotonin reuptake inhibitors; tamoxifen

PMID:
21709817
PMCID:
PMC3119576
DOI:
10.1586/ecp.11.18
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center